CO6791565A2 - Anticuerpos anti-notch1 - Google Patents

Anticuerpos anti-notch1

Info

Publication number
CO6791565A2
CO6791565A2 CO13158445A CO13158445A CO6791565A2 CO 6791565 A2 CO6791565 A2 CO 6791565A2 CO 13158445 A CO13158445 A CO 13158445A CO 13158445 A CO13158445 A CO 13158445A CO 6791565 A2 CO6791565 A2 CO 6791565A2
Authority
CO
Colombia
Prior art keywords
notch1 antibodies
notch1
antibodies
Prior art date
Application number
CO13158445A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth G Geles
Bin-Bing Stephen Zhou
Lioudmila Tchistiakova
Yijie Gao
Joel Bard
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CO6791565A2 publication Critical patent/CO6791565A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
CO13158445A 2010-12-15 2013-07-04 Anticuerpos anti-notch1 CO6791565A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42357810P 2010-12-15 2010-12-15
US201161552578P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
CO6791565A2 true CO6791565A2 (es) 2013-11-14

Family

ID=45444674

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13158445A CO6791565A2 (es) 2010-12-15 2013-07-04 Anticuerpos anti-notch1

Country Status (19)

Country Link
US (2) US9127060B2 (enExample)
EP (1) EP2651977A2 (enExample)
JP (1) JP6016800B2 (enExample)
KR (2) KR101580726B1 (enExample)
CN (2) CN105884896A (enExample)
AR (1) AR084315A1 (enExample)
AU (2) AU2011342799B2 (enExample)
BR (1) BR112013015122A2 (enExample)
CA (1) CA2821130C (enExample)
CO (1) CO6791565A2 (enExample)
MX (1) MX346995B (enExample)
NZ (1) NZ611785A (enExample)
PE (1) PE20141109A1 (enExample)
PH (2) PH12013501255A1 (enExample)
RU (1) RU2622083C2 (enExample)
SA (1) SA111330060B1 (enExample)
SG (1) SG191039A1 (enExample)
TW (1) TWI471333B (enExample)
WO (1) WO2012080926A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
NZ597611A (en) 2009-06-18 2014-03-28 Pfizer Anti notch-1 antibodies
KR101580726B1 (ko) 2010-12-15 2015-12-29 와이어쓰 엘엘씨 항-노치1 항체
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
CA2885659A1 (en) * 2012-09-21 2014-03-27 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with notch1 antibodies
RU2015116480A (ru) 2012-11-07 2016-12-27 Пфайзер Инк. Анти-notch3 антитела и конъюганты антител с лекарственным средством
RU2017103289A (ru) 2014-07-11 2018-08-14 Дженентек, Инк. Ингибирование пути notch
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
SG10202006332PA (en) * 2015-10-29 2020-08-28 Hoffmann La Roche Transgenic rabbit with common light chain
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
EP3743057A4 (en) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary TREATMENT OF HEARING LOSS
AU2019252878B2 (en) * 2018-04-10 2024-02-22 Stichting Sanquin Bloedvoorziening Chimeric Notch receptors
EP3856343A1 (en) * 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
KR102499678B1 (ko) * 2020-02-27 2023-02-15 주식회사 베르티스 암의 진단용 조성물
EP4206226A4 (en) * 2020-08-31 2024-10-16 Medytox Inc. Anti-vegf hexameric antibody and composition comprising same
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002526109A (ja) * 1998-10-02 2002-08-20 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ アポトーシス誘導物質と方法
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN1331214A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人缺刻蛋白24.64和编码这种多肽的多核苷酸
WO2002059285A1 (en) 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
CN1376686A (zh) * 2001-03-22 2002-10-30 上海博德基因开发有限公司 一种多肽——缺刻蛋白－34.32和编码这种多肽的多核苷酸
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
US20030148954A1 (en) 2001-11-02 2003-08-07 Wisconsin Alumni Research Foundation Agents and methods for modulating activator protein-1-mediated cellular processes
JP2005526701A (ja) 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
JPWO2003085107A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 ゲノムが改変された細胞
US7666982B2 (en) 2002-07-18 2010-02-23 Masayasu Okochi Notch-origin polypeptides and biomarkers and reagents using the same
SI2270048T1 (sl) 2002-12-24 2016-01-29 Rinat Neuroscience Corp. Protitelesa proti NGF-ju in postopki uporabe le-teh
AU2004294563B2 (en) 2003-11-26 2009-03-26 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
US20080220416A1 (en) 2004-05-20 2008-09-11 The Board Of Trustees Of The University Of Illinoi Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
NZ555216A (en) * 2004-11-10 2010-05-28 Hubrecht Lab Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
CN105085678B (zh) 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
US20080206753A1 (en) 2005-03-04 2008-08-28 The Hospital For Sick Children Methods for Cancer Prognosis
US20070072222A1 (en) 2005-09-23 2007-03-29 Franziska Boess FABP4 as biomarker for toxic effect
WO2007061988A2 (en) 2005-11-22 2007-05-31 University Of Vermont And State Agricultural College Methods for determining notch signaling and uses thereof
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
CN101605815B (zh) * 2006-12-18 2013-11-13 健泰科生物技术公司 拮抗性抗刻缺蛋白3抗体及其在预防和治疗刻缺蛋白3相关疾病中的用途
US20100062012A1 (en) 2007-03-05 2010-03-11 Ioannides Constantin G Negative Genetic Regulation of Cancer Cell Renewal in Synergy with Notch- or Numb-Specific Immunotherapy
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2899211A1 (en) 2008-07-08 2015-07-29 OncoMed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
NZ597611A (en) 2009-06-18 2014-03-28 Pfizer Anti notch-1 antibodies
JP6025563B2 (ja) 2009-09-30 2016-11-16 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性癌の治療
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
WO2012080891A1 (en) 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
KR101580726B1 (ko) 2010-12-15 2015-12-29 와이어쓰 엘엘씨 항-노치1 항체

Also Published As

Publication number Publication date
CA2821130C (en) 2017-11-07
CN103547594A (zh) 2014-01-29
PH12017500864A1 (en) 2017-12-11
CA2821130A1 (en) 2012-06-21
HK1194388A1 (zh) 2014-10-17
JP6016800B2 (ja) 2016-10-26
AR084315A1 (es) 2013-05-08
WO2012080926A2 (en) 2012-06-21
AU2011342799A1 (en) 2013-07-04
US20130266594A1 (en) 2013-10-10
US20160002331A1 (en) 2016-01-07
RU2622083C2 (ru) 2017-06-09
SA111330060B1 (ar) 2015-06-04
KR101580726B1 (ko) 2015-12-29
KR20130108430A (ko) 2013-10-02
PE20141109A1 (es) 2014-09-24
AU2016219704A1 (en) 2016-09-15
BR112013015122A2 (pt) 2017-05-30
CN103547594B (zh) 2016-05-11
JP2014503205A (ja) 2014-02-13
RU2013126494A (ru) 2015-01-20
WO2012080926A3 (en) 2012-10-04
EP2651977A2 (en) 2013-10-23
TW201302787A (zh) 2013-01-16
TWI471333B (zh) 2015-02-01
KR20150088334A (ko) 2015-07-31
SG191039A1 (en) 2013-08-30
MX2013006875A (es) 2013-07-05
CN105884896A (zh) 2016-08-24
NZ611785A (en) 2015-04-24
PH12013501255A1 (en) 2013-08-05
MX346995B (es) 2017-04-06
US9127060B2 (en) 2015-09-08
AU2011342799B2 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
CY2019040I2 (el) Aνti-il-23 αντισωματα
LTPA2019011I1 (lt) CGRP antikūnai
BR112012030311A2 (pt) anticorpo
HUE038962T2 (hu) DLL3-ellenes antitest
IL222272B (en) Anti-erbb3 antibodies
CO6791565A2 (es) Anticuerpos anti-notch1
DK2521736T3 (da) Humaniserede antistoffer
PT2406284T (pt) Anticorpos anti-bcma
DK3284754T3 (da) Anti-cd38-antistoffer
DK3178851T3 (da) Anti-cd40-antistoffer
DK3323830T3 (da) Anti-gd2 antibodies
DK3741883T5 (da) Antistofbiblioteker
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
DE10170954T8 (de) Mikrowellendruckgarer
CR20130228A (es) Anticuerpos neutralizadores anti-ccl20
DK3202789T3 (da) Anti-vla-4-antistoffer
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011101226A5 (de) Linearwegmesssystem
DE102010038420A8 (de) Reinigungungsvorrichtung
DE102011002623A8 (de) Ventilsteuerzeitversteller
DE102010035554B8 (de) Fußtüröffner
DE102010019119B8 (de) Cuttermesser
DE112010005518A5 (de) Dichtungsmanchette

Legal Events

Date Code Title Description
FG Application granted